Ask AI
ASH 2025 MDS and MPNs

CE / CME

New Data and Clinical Implications in MPNs and MDS: ASH 2025 Highlights

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 26, 2026

Expiration: August 25, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31:1531-1538.
  2. Rampal R, Mascarenhas J, Grosicki S, et al. Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK inhibitor–naive myelofibrosis: 96-week results from the phase III MANIFEST-2 study. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 910.
  3. Gupta V, Mascarenhas J, Ali H, et al. Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 1024.
  4. Mascarenhas J, Al-Ali HK, Gupta V, et al. Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): preliminary results from dose escalation of two global phase 1 studies. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 484.
  5. Garcia-Manero G, Platzbecker U, Fenaux P, et al. Primary analysis of the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-naïve, intermediate and higher-risk myelodysplastic syndromes. Clini Lymphoma Myeloma and Leuk. 2025;25:S644-S645.
  6. Garcia-Manero G, Platzbecker U, Fenaux P, et al. Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS). Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 235.
  7. Imetelstat [prescribing information]. Foster City, CA: Geron Corporation; 2024.
  8. Zeidan A, Santini V, Diez-Campelo M, et al. Correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with lower-risk myelodysplastic syndromes: analysis from the IMerge trial. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 490.
  9. Bouligny I, Carraway H, Sekeres M, et al. A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk myelodysplastic syndromes. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 487.
  10. Decitabine and cedazuridine [prescribing information]. Princeton, NJ: Taiho Oncology, Inc; 2020.